Chronic hepatitis C in HIV-HCV coinfected patients;Hépatite chronique C chez les malades infectés par le virus de l'immunodeficience humaine

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Gervais, Anne ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIRETROVIRUS AGENT; INTERLEUKIN 2; PEGINTERFERON; RIBAVIRIN; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CHRONIC HEPATITIS; COMORBIDITY; CONFERENCE PAPER; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREVALENCE; VIRAL CONTAMINATION; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; AMANTADINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHILD; CLINICAL TRIALS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; META-ANALYSIS; PILOT PROJECTS; PREVALENCE; RIBAVIRIN; RISK FACTORS;

EID: 17044449732     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (130)

1. A national survey in the departments of internal medicine and infectious diseases
2. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
3. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection
4. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C, UK Haemophilia Centre Directors' Organisation
5. Mortality for liver disease in patients with HIV infection: A cohort study
6. Prévalence des coinfections par le virus de l'hépatite B (VHB) et le virus cle l'hépatite C (VHC) dans une cohorte de malades infectés par le VIH et traités par inhibiteurs de protéases
7. Salmon-Céron D et l'APPIT. Epidémiologie hospitalière des malades coinfectés par le VIH et le VHC
8. Infections à VIH, VHC et VHB chez les résidents des centres de soins spécialisés pour toxicomanes avec hébergement 1993-1998
9. Correlates of hepatitis C virus infections among injection drug users
10. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study
11. Evidence of sexual transmission of Hepatitis C Virus (HCV) in a cohort of homosexual men
12. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - An analysis of 309 sex partnerships
13. Hepatitis C. hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases
14. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings
15. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
16. Etude multicentrique de la transmission intrafamiliaie du virus de l'hépatite C dans le contexte de l'infection par le virus de l'immunodéficience humaine
17. Virus de l'hépatite C et grossesse
18. Human immunodeficiency virus infection as a risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother immunoblotting pattern
19. Mother-to-infant transmission of hepatitis C virus
20. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1
21. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection
22. Perinatal transmission et hepatitis C virus from human immunodeficiency virus type-1 infected mothers
23. Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women
24. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations
25. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus
26. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay
27. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
28. Motifs de non-traitement de l'infection par le VHC chez des malades infectés par le VIH
29. Hepatitis C. the clinical spectrum of the disease
30. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
31. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: A case-control study
32. Hepatitis C virus-infected, HCV-RNA-negative patients with bleeding disorders. Relationship to age, HIV and treatment
33. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985
34. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia
35. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
36. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
37. Patients coinfected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA
38. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
39. Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders
40. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
41. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection
42. Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV-HCV coinfected patients
43. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
44. The progression of HCV-associated liver disease in a cohort of haemophilic patients
45. The natural history of chronic hepatitis C in haemophiliacs
46. Predictive factors for developement of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
47. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
48. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV
49. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs
50. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study
51. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis
52. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection
53. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C
54. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997
55. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy
56. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
57. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
58. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus
59. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type I
60. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes
61. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to survival
62. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS
63. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users
64. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival
65. Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV-HCV-coinfected patients
66. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
67. Two decades of HIV infection in a cohort of haemophilic individuals: Clinical outcomes and response to highly active antiretroviral therapy
68. Predictors of protease inhibitor-associated adverse events
69. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
70. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
71. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
72. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART
73. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
74. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
75. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
76. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
77. Enhancement of hepatitis C virus replication and liver damage in HIV coinfected patients on antiretroviral combination therapy
78. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?
79. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy
80. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV coinfected haemophiliacs
81. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects
82. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients
83. Can HCV affect the efficacy of anti-HIV treatment?
84. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIVHCV coinfected patients
85. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
86. Hepatitis C viraemia in HIV-HCV coinfected patients having immune restoration with highly active antiretroviral therapy
87. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
88. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy
89. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients
90. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment
91. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection
92. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients
93. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
94. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs
95. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count
96. Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon
97. Interferon treatment of two patients with quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV)
98. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
99. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients
100. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: Efficacy, tolerance, and response related factors
101. Aggressive daily interferon therapy in HIV-HCV coinfected patients
102. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients
103. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study
104. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection
105. CD4+ T Lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C
106. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders
107. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
108. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
109. Long-term efficacy of combination therapy with interferon-alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
110. Efficacy and safety of combination therapy with interferonalpha2b and ribavirin for chronic hepatitis C in HIV-infected patients
111. Effect of interferon and ribavirin on HIV viral load
112. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
113. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin
114. Chronic hepatitis C in HIV-coinfected patients: Feasibility and efficacy of interferon-alpha-2b and ribavirin combination therapy
115. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy
116. Combination treatment for hepatitis C can be hazardous in patients coinfected with HIV
117. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders
118. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
119. Mitochondrial toxic effects and ribavirin
120. Risque d'acidose lactique chez des malades co-infectés par VIH et VHC et traités par ribavirine-interferon et trithérapie antirétrovirale
121. Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy
122. Recombinant interleukine 2 for treatment of HIV reduces hepatitis C viral load in coinfected patients
123. Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus coinfected patients
124. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV)
125. Liver transplantation in adults coinfected with HIV
126. Solid organ transplantation in HIV disease